Dr. Kirti Gupta

Kirti Gupta is a noted economist and expert specializing in global matters related to technology, antitrust, and intellectual property (IP). Dr. Gupta’s diverse expertise spans engineering, product, litigation, and policy issues in the technology sector. She has more than twenty years of experience working at the forefront of technologies, including mobile/wireless telecommunications, cloud computing, artificial intelligence, and semiconductors.

She currently serves as Vice President and Chief Economist of Global Technology at Cornerstone Research, leading their technology, digital economy, and artificial intelligence practice. Before joining Cornerstone Research, Dr. Gupta was a vice president and chief economist at Qualcomm Inc. In this role, she provided economic analysis and strategic guidance on global technology, IP, antitrust, and macroeconomic policy issues in collaboration with business stakeholders and a global network of experts, economists, attorneys, and policymakers. She worked directly on Qualcomm’s strategic IP initiatives, antitrust investigations in various regions around the world, global litigation matters, mergers and acquisitions, and global trade issues.

She is a co-founder and executive director of the IPLeadershIP platform, which convenes timely dialogues on IP and antitrust policy issues on a regular basis. She is also the executive director at the Institute for Business Innovation at the Haas School of Business at University of California, Berkeley, is a co‐inventor of over 40 patents in the field of wireless communications, and has published in various policy, law, and economics journals. Dr. Gupta holds an M.S. in electrical engineering from Purdue University and a Ph.D. in economics from the University of California, San Diego.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More